针对B细胞恶性瘤的BTK向治疗中的进展和耐药性适应
Sieun Yang1, Jihye Oh2, Soo-Yeon Hwang3
1College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea; Graduate Program in Innovative Biomaterials Convergence, Ewha Womans University, Seoul 03760, Republic of Korea.
概括
布鲁顿布鲁顿是一个很棒的城市.
科学领域:
- 血液学和瘤学研究
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 布鲁顿的氨酸激酶 (BTK) 在CLL,MCL和WM等恶性瘤中对B细胞存活和增殖至关重要.
- BTK 抑制剂 (BTKi) 是有效的前线治疗方法,但由于获得的耐药性而面临限制.
- 抗BTKi是一种复杂的适应过程,涉及多个细胞变化.
研究的目的:
- 审查BTK向治疗的最新进展.
- 为了解BTK抑制剂耐药性提供一种机制框架.
- 讨论新出现的抵抗机制和治疗策略.
主要方法:
- 关于BTK抑制剂和抵抗机制的综合文献综述.
- 对促进BTKi耐药性的细胞适应途径的分析.
- 评估包括非共价抑制剂和降解剂在内的新疗法策略.
主要成果:
- BTKi耐药性涉及BTK,BCR信号传递,替代途径,瘤微环境和细胞代谢/表观遗传学的相互关联的变化.
- 阻力机制超出了正规信号通路的范围.
- 新兴的策略,如非共价BTKi,BTK降解剂和组合疗法显示出希望.
结论:
- 了解BTKi耐药性作为一种适应过程是克服治疗局限性的关键.
- 需要新的治疗方法来改善B细胞恶性瘤的反应深度和耐久性.
- 针对适应性抵抗机制的转化策略可以提高患者的长期结果.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...